FR17C1020I2 - RECOMBINANT FSH INCLUDING ALPHA 2.3 AND ALPHA 2.6 SIALYLATION - Google Patents

RECOMBINANT FSH INCLUDING ALPHA 2.3 AND ALPHA 2.6 SIALYLATION

Info

Publication number
FR17C1020I2
FR17C1020I2 FR17C1020C FR17C1020C FR17C1020I2 FR 17C1020 I2 FR17C1020 I2 FR 17C1020I2 FR 17C1020 C FR17C1020 C FR 17C1020C FR 17C1020 C FR17C1020 C FR 17C1020C FR 17C1020 I2 FR17C1020 I2 FR 17C1020I2
Authority
FR
France
Prior art keywords
alpha
sialylation
recombinant fsh
fsh including
including alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1020C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1020(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Application granted granted Critical
Publication of FR17C1020I1 publication Critical patent/FR17C1020I1/fr
Publication of FR17C1020I2 publication Critical patent/FR17C1020I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR17C1020C 2008-04-16 2017-06-06 RECOMBINANT FSH INCLUDING ALPHA 2.3 AND ALPHA 2.6 SIALYLATION Active FR17C1020I2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP13193214.7A EP2722339A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP14178729.1A EP2808340B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP09733497.3A EP2268666B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (2)

Publication Number Publication Date
FR17C1020I1 FR17C1020I1 (en) 2020-04-10
FR17C1020I2 true FR17C1020I2 (en) 2020-04-10

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
FR17C1020C Active FR17C1020I2 (en) 2008-04-16 2017-06-06 RECOMBINANT FSH INCLUDING ALPHA 2.3 AND ALPHA 2.6 SIALYLATION

Country Status (29)

Country Link
US (5) US8951967B2 (en)
EP (7) EP3098234A1 (en)
JP (7) JP2011519359A (en)
KR (5) KR20170110741A (en)
CN (3) CN105906703A (en)
AR (1) AR071479A1 (en)
AU (5) AU2009237479B2 (en)
BR (1) BRPI0910461B8 (en)
CA (1) CA2725257A1 (en)
CY (1) CY1115413T1 (en)
DK (4) DK3144318T3 (en)
ES (3) ES2468318T3 (en)
FR (1) FR17C1020I2 (en)
HK (2) HK1146284A1 (en)
HR (3) HRP20140535T1 (en)
HU (5) HUE030652T4 (en)
IL (2) IL208538A (en)
LT (4) LT2808340T (en)
MX (3) MX2010011343A (en)
NO (2) NO2017025I1 (en)
NZ (1) NZ588381A (en)
PL (4) PL3144318T3 (en)
PT (4) PT3144318T (en)
RU (3) RU2682270C2 (en)
SA (1) SA109300228B1 (en)
SI (4) SI3144318T1 (en)
TW (1) TWI488640B (en)
WO (1) WO2009127826A1 (en)
ZA (1) ZA201007373B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (en) 2008-04-16 2015-06-21 Ferring Int Ct Sa Pharmaceutical preparation
TWI532495B (en) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HRP20150968T4 (en) 2010-09-29 2023-11-10 Ferring B.V. Composition for use in treating infertility
CN103154243A (en) 2010-10-15 2013-06-12 日本化学研究株式会社 Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
CN103619358B (en) * 2011-03-31 2017-02-15 辉凌公司 Pharmaceutical preparation
AR090095A1 (en) 2011-06-06 2014-10-22 Ferring Bv PHARMACEUTICAL PREPARATION THAT INCLUDES STIMULATING HORMONE OF THE RECOMBINANT FOLICLE
JO3092B1 (en) 2011-08-08 2017-03-15 Ferring Bv Composition for controlled ovarian stimulation
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (en) * 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 New expression vector
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (en) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 Medium containing uridine and N-acetyl-D-mannosamine
CN107429237B (en) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 CMP-dependent sialidase Activity
RU2704252C2 (en) 2015-04-17 2019-10-25 Ферринг Б.В. Composition for treating infertility
MX2017016437A (en) 2015-06-26 2018-03-02 Ferring Bv Methods of purification and/or viral inactivation.
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
ES2904787T3 (en) 2017-09-01 2022-04-06 Ferring Bv Composition for controlled ovarian stimulation
EP3787667A1 (en) 2018-04-30 2021-03-10 Ferring B.V. Composition for controlled ovarian stimulation
CN112789053A (en) 2018-10-17 2021-05-11 辉凌公司 Compositions and methods for controlled ovarian stimulation
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (en) 2020-12-09 2022-10-01 荷蘭商菲林公司 Compositions and methods for controlled ovarian stimulation
WO2023186331A1 (en) 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (en) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca URINARY FOLLICLE-STIMULATING HORMONE
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
ES2333425T5 (en) 1995-06-15 2012-08-28 Crucell Holland B.V. Packaging systems for human recombinant adenovirus intended for gene therapy
JP3559652B2 (en) * 1996-06-25 2004-09-02 グローリー工業株式会社 Management device for sales settlement system
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
DK1015622T3 (en) 1997-01-16 2004-08-02 Neose Technologies Inc Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (en) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd Sterilized pneumatic conveyor device
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
WO2003048348A2 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
CN1352566A (en) 1999-05-07 2002-06-05 应用研究系统Ars股份公司 Gonadotrophins
JP2002011665A (en) 2000-06-28 2002-01-15 Sintokogio Ltd Shot blast device monbitoring system
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
EA007030B1 (en) * 2001-10-22 2006-06-30 Апплайд Резеч Системз Арс Холдинг Н.В. Gonadotrophines for folliculogenesis
AU2002335585B2 (en) 2001-10-29 2007-08-16 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
ATE476666T1 (en) 2004-02-04 2010-08-15 Centre Nat Rech Scient METHOD FOR IDENTIFYING GLYCOFORM-SPECIFIC ANTIBODIES
CN103627670B (en) * 2004-02-13 2016-12-21 格莱克托普有限公司 High activity glycoprotein processing conditions and effectively production method
TWI488640B (en) 2008-04-16 2015-06-21 Ferring Int Ct Sa Pharmaceutical preparation
TWI532495B (en) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016575A1 (en) 2010-08-03 2012-02-09 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HRP20150968T4 (en) 2010-09-29 2023-11-10 Ferring B.V. Composition for use in treating infertility
CN103619358B (en) 2011-03-31 2017-02-15 辉凌公司 Pharmaceutical preparation
AR090095A1 (en) 2011-06-06 2014-10-22 Ferring Bv PHARMACEUTICAL PREPARATION THAT INCLUDES STIMULATING HORMONE OF THE RECOMBINANT FOLICLE
JO3092B1 (en) 2011-08-08 2017-03-15 Ferring Bv Composition for controlled ovarian stimulation
CN106413735A (en) 2014-04-18 2017-02-15 葛莱高托普有限公司 Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
KR20180095140A (en) 2018-08-24
EP2808340A1 (en) 2014-12-03
AU2014203277A1 (en) 2014-07-24
KR20160056960A (en) 2016-05-20
BRPI0910461A8 (en) 2018-10-16
ZA201007373B (en) 2011-06-29
RU2014141994A3 (en) 2018-05-28
PT2268666E (en) 2014-06-25
AU2017225020A1 (en) 2017-09-28
NZ588381A (en) 2012-05-25
AU2017204259B2 (en) 2017-08-17
LTPA2017029I1 (en) 2017-10-10
RU2745557C3 (en) 2021-12-10
LT3045471T (en) 2017-07-10
HUE030652T4 (en) 2017-09-28
MX2010011343A (en) 2011-01-20
KR101622944B1 (en) 2016-05-23
JP2020040956A (en) 2020-03-19
FR17C1020I1 (en) 2020-04-10
HUE033830T2 (en) 2018-01-29
AU2014203277B2 (en) 2017-04-06
EP3144318A1 (en) 2017-03-22
EP2268666A1 (en) 2011-01-05
RU2014141994A (en) 2016-05-10
LTPA2017018I1 (en) 2017-06-26
PL3144318T3 (en) 2021-02-08
IL208538A0 (en) 2010-12-30
JP2017060476A (en) 2017-03-30
US9771407B2 (en) 2017-09-26
PT3144318T (en) 2020-11-04
AU2017204259A1 (en) 2017-07-20
SI2268666T1 (en) 2014-07-31
HUS1700024I1 (en) 2017-06-28
AR071479A1 (en) 2010-06-23
US20180079794A1 (en) 2018-03-22
PL2268666T3 (en) 2014-08-29
CA2725257A1 (en) 2009-10-22
DK2808340T3 (en) 2016-12-05
MX348622B (en) 2017-06-22
IL208538A (en) 2014-03-31
IL230571A (en) 2015-11-30
TW200948378A (en) 2009-12-01
US8951967B2 (en) 2015-02-10
DK2268666T3 (en) 2014-05-12
NO2017050I1 (en) 2017-09-28
US9546204B2 (en) 2017-01-17
ES2629392T3 (en) 2017-08-09
AU2017204258B2 (en) 2017-08-17
PL3045471T3 (en) 2017-10-31
DK3144318T3 (en) 2020-12-07
PT3045471T (en) 2017-06-14
CN105906703A (en) 2016-08-31
ES2468318T3 (en) 2014-06-16
WO2009127826A1 (en) 2009-10-22
AU2009237479B2 (en) 2014-05-15
EP3098234A1 (en) 2016-11-30
HUS1700025I1 (en) 2017-06-28
EP2808340B1 (en) 2016-08-17
KR20190092608A (en) 2019-08-07
JP2011519359A (en) 2011-07-07
JP7316905B2 (en) 2023-07-28
EP3045471B1 (en) 2017-03-29
HUE030652T2 (en) 2017-05-29
CN105906702A (en) 2016-08-31
LT2808340T (en) 2016-11-10
HK1146284A1 (en) 2011-05-20
JP6762916B2 (en) 2020-09-30
JP2015120696A (en) 2015-07-02
CY1115413T1 (en) 2017-01-04
US20210332099A1 (en) 2021-10-28
US11952407B2 (en) 2024-04-09
DK3045471T3 (en) 2017-06-26
EP3045471A1 (en) 2016-07-20
AU2017225020B2 (en) 2019-11-14
US20110105398A1 (en) 2011-05-05
HRP20161520T1 (en) 2016-12-30
NO2017025I1 (en) 2017-06-06
RU2745557C1 (en) 2021-03-29
AU2017204258A1 (en) 2017-07-20
KR20170110741A (en) 2017-10-11
JP2022031652A (en) 2022-02-22
RU2682270C2 (en) 2019-03-18
EP4015527A1 (en) 2022-06-22
CN102066414A (en) 2011-05-18
EP2722339A1 (en) 2014-04-23
SI3045471T1 (en) 2017-07-31
BRPI0910461B8 (en) 2021-05-25
HRP20170958T1 (en) 2017-09-22
US10995128B2 (en) 2021-05-04
RU2537268C2 (en) 2014-12-27
JP2018021037A (en) 2018-02-08
AU2014203277C1 (en) 2017-07-27
HK1199039A1 (en) 2015-06-19
SI2808340T1 (en) 2016-12-30
SI3144318T1 (en) 2020-12-31
BRPI0910461A2 (en) 2018-03-27
AU2009237479A1 (en) 2009-10-22
EP2268666B1 (en) 2014-03-12
ES2610277T3 (en) 2017-04-26
HRP20140535T1 (en) 2014-07-18
KR20110005863A (en) 2011-01-19
PT2808340T (en) 2016-11-21
PL2808340T3 (en) 2017-02-28
SA109300228B1 (en) 2014-04-08
KR102108377B1 (en) 2020-05-08
EP3144318B1 (en) 2020-09-23
US20160347811A1 (en) 2016-12-01
RU2010141908A (en) 2012-05-27
BRPI0910461B1 (en) 2021-02-23
US20150065695A1 (en) 2015-03-05
MX355457B (en) 2018-04-19
JP6486310B2 (en) 2019-03-20
JP2024038000A (en) 2024-03-19
HUS1700036I1 (en) 2017-10-30
TWI488640B (en) 2015-06-21

Similar Documents

Publication Publication Date Title
FR17C1020I2 (en) RECOMBINANT FSH INCLUDING ALPHA 2.3 AND ALPHA 2.6 SIALYLATION
ITVE20060045A1 (en) HEATER FOR SHOES, GLOVES AND THE LIKE.
BRPI0815773A2 (en) compound and medicine.
BRPI0816970A2 (en) 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones
BRPI0815922A2 (en) ARTICLE, COMPOSITION, AND METHOD.
Meroni et al. CRAWDAD dataset unimi/pmtr (v. 2008-12-01)
JP2012513655A5 (en)
BRPI0923402A2 (en) C10rf59 peptides and vaccines including the same.
BRPI0919168A2 (en) mutant pestivirus and vaccine.
Eser Palleh Hyongbop Chongnon, Bulpopgwa Choungdanghwae Gwanhan Ilbanwonchik
HUE051918T2 (en) Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
TH103053B (en) Franchise add-on system with the patient's operating terminal and the store floor, storefront and reserve floor.
TH71292B (en) A long-chain-branched propylene-alpha-olefin copolymer.
CN301071626S (en) Bus (EQ6750P3G)
TH113134S (en) Chairs for the toilet.
ES1059941Y (en) RODAPIE OR HEATING SKIRT.
ITPD20080088U1 (en) PERFECT STERILIZER STRUCTURE FOR DEVICES WITH BUTTONS, KEYS AND THE LIKE.
TH106419S (en) chair
TH111363S (en) chair
TH111364S (en) chair
TH111365S (en) chair
TH111883S (en) chair
TH106412S (en) chair
TH106414S (en) chair
TH106413S (en) chair